{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:16:48Z","timestamp":1788574608863,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1038\/s41591-022-02060-2","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T16:06:35Z","timestamp":1666886795000},"page":"2611-2621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-9314","authenticated-orcid":false,"given":"Lucia","family":"Bail\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0133-9888","authenticated-orcid":false,"given":"Anuska","family":"Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-0208","authenticated-orcid":false,"given":"Samandhy","family":"Cede\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-7802","authenticated-orcid":false,"given":"Tuixent","family":"Escrib\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-6586","authenticated-orcid":false,"given":"Miriam","family":"Ros\u00e1s-Umbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona","family":"Parera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4115-2305","authenticated-orcid":false,"given":"Maria","family":"Casadell\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2714-9097","authenticated-orcid":false,"given":"Bruna","family":"Oriol-Tordera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ruiz-Riol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c0ngel","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne R.","family":"Leselbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6470-8476","authenticated-orcid":false,"given":"Ian","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund G.","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6076-9546","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-691X","authenticated-orcid":false,"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-8634","authenticated-orcid":false,"given":"Yovaninna","family":"Alarc\u00f3n-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-4598","authenticated-orcid":false,"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-1395","authenticated-orcid":false,"given":"Marc","family":"Noguera-Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-5778","authenticated-orcid":false,"given":"Christian","family":"Brander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Molto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-407X","authenticated-orcid":false,"given":"Beatriz","family":"Mothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the AELIX002 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Barriocanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Benet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cobarsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romas","family":"Geleziunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne R.","family":"Leselbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora","family":"Loste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Meulbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Naval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroa","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2060_CR1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","volume":"36","author":"L Shan","year":"2012","unstructured":"Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491\u2013501 (2012).","journal-title":"Immunity"},{"key":"2060_CR2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","volume":"11","author":"B Mothe","year":"2019","unstructured":"Mothe, B. et al. Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study). EClinicalMedicine 11, 65\u201380 (2019).","journal-title":"EClinicalMedicine"},{"key":"2060_CR3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3389\/fimmu.2020.00823","volume":"11","author":"B Mothe","year":"2020","unstructured":"Mothe, B. et al. HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02). Front. Immunol. 11, 823 (2020).","journal-title":"Front. Immunol."},{"key":"2060_CR4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0140-6736(19)32990-3","volume":"395","author":"S Fidler","year":"2020","unstructured":"Fidler, S. et al. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet 395, 888\u2013898 (2020).","journal-title":"Lancet"},{"key":"2060_CR5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41591-020-0774-y","volume":"26","author":"DJ Colby","year":"2020","unstructured":"Colby, D. J. et al. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat. Med. 26, 498\u2013501 (2020).","journal-title":"Nat. Med."},{"key":"2060_CR6","doi-asserted-by":"crossref","first-page":"eaan8848","DOI":"10.1126\/scitranslmed.aan8848","volume":"9","author":"MC Sneller","year":"2017","unstructured":"Sneller, M. C. et al. A randomized controlled safety\/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci. Transl. Med. 9, eaan8848 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2060_CR7","doi-asserted-by":"crossref","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","volume":"11","author":"OS S\u00f8gaard","year":"2015","unstructured":"S\u00f8gaard, O. S. et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142 (2015).","journal-title":"PLoS Pathog."},{"key":"2060_CR8","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-9-208","volume":"9","author":"B Mothe","year":"2011","unstructured":"Mothe, B. et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J. Transl. Med. 9, 208 (2011).","journal-title":"J. Transl. Med."},{"key":"2060_CR9","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-015-0392-5","volume":"13","author":"B Mothe","year":"2015","unstructured":"Mothe, B. et al. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J. Transl. Med. 13, 60 (2015).","journal-title":"J. Transl. Med."},{"key":"2060_CR10","doi-asserted-by":"crossref","first-page":"e29717","DOI":"10.1371\/journal.pone.0029717","volume":"7","author":"B Mothe","year":"2012","unstructured":"Mothe, B. et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS ONE 7, e29717 (2012).","journal-title":"PLoS ONE"},{"key":"2060_CR11","doi-asserted-by":"crossref","first-page":"e1004658","DOI":"10.1371\/journal.ppat.1004658","volume":"11","author":"G Hancock","year":"2015","unstructured":"Hancock, G. et al. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. PLoS Pathog. 11, e1004658 (2015).","journal-title":"PLoS Pathog."},{"key":"2060_CR12","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1016\/j.vaccine.2010.12.056","volume":"29","author":"V Kulkarni","year":"2011","unstructured":"Kulkarni, V. et al. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine 29, 6742\u20136754 (2011).","journal-title":"Vaccine"},{"key":"2060_CR13","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1371\/journal.pone.0000984","volume":"2","author":"S L\u00e9tourneau","year":"2007","unstructured":"L\u00e9tourneau, S. et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2, e984 (2007).","journal-title":"PLoS ONE"},{"key":"2060_CR14","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","volume":"7","author":"MDJ Dicks","year":"2012","unstructured":"Dicks, M. D. J. et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 7, e40385 (2012).","journal-title":"PLoS ONE"},{"key":"2060_CR15","first-page":"2258","volume":"75","author":"\u00c1 Bay\u00f3n-Gil","year":"2020","unstructured":"Bay\u00f3n-Gil, \u00c1. et al. HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design. J. Antimicrob. Chemother. 75, 2258\u20132263 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"2060_CR16","doi-asserted-by":"publisher","unstructured":"Goulder, P. J. R. & Walker, B. D. HIV and HLA Class I: an evolving relationship. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2012.09.005 (2012).","DOI":"10.1016\/j.immuni.2012.09.005"},{"key":"2060_CR17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/infdis\/jis379","volume":"206","author":"H Yang","year":"2012","unstructured":"Yang, H. et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J. Infect. Dis. 206, 552\u2013561 (2012).","journal-title":"J. Infect. Dis."},{"key":"2060_CR18","doi-asserted-by":"crossref","first-page":"e0208107","DOI":"10.1371\/journal.pone.0208107","volume":"13","author":"RN Werner","year":"2018","unstructured":"Werner, R. N., Gaskins, M., Nast, A. & Dressler, C. Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection\u2014a meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. PLoS ONE 13, e0208107 (2018).","journal-title":"PLoS ONE"},{"key":"2060_CR19","doi-asserted-by":"crossref","first-page":"e141677","DOI":"10.1172\/JCI141677","volume":"131","author":"AA Okoye","year":"2021","unstructured":"Okoye, A. A. et al. CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification. J. Clin. Invest. 131, e141677 (2021).","journal-title":"J. Clin. Invest."},{"key":"2060_CR20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature14053","volume":"517","author":"K Deng","year":"2015","unstructured":"Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381\u2013385 (2015).","journal-title":"Nature"},{"key":"2060_CR21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","volume":"563","author":"EN Borducchi","year":"2018","unstructured":"Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360\u2013364 (2018).","journal-title":"Nature"},{"key":"2060_CR22","doi-asserted-by":"crossref","first-page":"e01986920","DOI":"10.1128\/JVI.01986-20","volume":"95","author":"C Gaebler","year":"2021","unstructured":"Gaebler, C. et al. Sequence evaluation and comparative analysis of novel assays for intact proviral HIV-1 DNA. J. Virol. 95, e01986920 (2021).","journal-title":"J. Virol."},{"key":"2060_CR23","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41591-020-1022-1","volume":"26","author":"A-M M","year":"2020","unstructured":"M, A.-M. et al. Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nat. Med. 26, 1339\u20131350 (2020).","journal-title":"Nat. Med."},{"key":"2060_CR24","doi-asserted-by":"crossref","first-page":"eabg3071","DOI":"10.1126\/scitranslmed.abg3071","volume":"13","author":"D SenGupta","year":"2021","unstructured":"SenGupta, D. et al. The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. Sci. Transl. Med. 13, eabg3071 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2060_CR25","doi-asserted-by":"crossref","first-page":"e101591","DOI":"10.1371\/journal.pone.0101591","volume":"9","author":"E-J Hayton","year":"2014","unstructured":"Hayton, E.-J. et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS ONE 9, e101591 (2014).","journal-title":"PLoS ONE"},{"key":"2060_CR26","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 384, 2092\u20132101 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2060_CR27","doi-asserted-by":"publisher","unstructured":"Namazi, G. et al. The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiy479 (2018).","DOI":"10.1093\/infdis\/jiy479"},{"key":"2060_CR28","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","volume":"6","author":"B Julg","year":"2019","unstructured":"Julg, B. et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials\u2014report of a consensus meeting. Lancet HIV 6, e259\u2013e268 (2019).","journal-title":"Lancet HIV"},{"key":"2060_CR29","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1097\/QAD.0000000000002978","volume":"35","author":"JM Fajnzylber","year":"2021","unstructured":"Fajnzylber, J. M. et al. Frequency of post treatment control varies by ART restart and viral load criteria. AIDS 35, 2225\u20132227 (2021).","journal-title":"AIDS"},{"key":"2060_CR30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/25787489.2021.1902116","volume":"22","author":"K Dub\u00e9","year":"2021","unstructured":"Dub\u00e9, K. et al. Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research. HIV Res. Clin. Pract. 22, 14\u201330 (2021).","journal-title":"HIV Res. Clin. Pract."},{"key":"2060_CR31","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/cid\/ciaa1260","volume":"72","author":"MJ Peluso","year":"2021","unstructured":"Peluso, M. J. et al. Operationalizing HIV cure-related trials with analytic treatment interruptions during the SARS-CoV-2 pandemic: a collaborative approach. Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am. 72, 1843\u20131849 (2021).","journal-title":"Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am."},{"key":"2060_CR32","doi-asserted-by":"crossref","first-page":"100025","DOI":"10.1016\/j.jve.2020.100025","volume":"7","author":"S Fidler","year":"2021","unstructured":"Fidler, S. et al. HIV cure research in the time of COVID-19\u2014antiretroviral therapy treatment interruption trials: a discussion paper. J. Virus Erad. 7, 100025 (2021).","journal-title":"J. Virus Erad."},{"key":"2060_CR33","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(20)30234-4","volume":"8","author":"SR Lewin","year":"2021","unstructured":"Lewin, S. R. et al. Multi-stakeholder consensus on a target product profile for an HIV cure. Lancet HIV 8, e42\u2013e50 (2021).","journal-title":"Lancet HIV"},{"key":"2060_CR34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559\u2013563 (2017).","journal-title":"Nature"},{"key":"2060_CR35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"2060_CR36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000600","volume":"15","author":"M Caskey","year":"2020","unstructured":"Caskey, M. Broadly neutralizing antibodies for the treatment and prevention of HIV infection. Curr. Opin. HIV AIDS 15, 49\u201355 (2020).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2060_CR37","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00002030-200309050-00005","volume":"17","author":"EW Fiebig","year":"2003","unstructured":"Fiebig, E. W. et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17, 1871\u20131879 (2003).","journal-title":"AIDS"},{"key":"2060_CR38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41409-018-0114-8","volume":"53","author":"E Enrich","year":"2018","unstructured":"Enrich, E. et al. Analysis of the Spanish CCR5-\u039432 inventory of cord blood units: lower cell counts in homozygous donors. Bone Marrow Transpl. 53, 741\u2013748 (2018).","journal-title":"Bone Marrow Transpl."},{"key":"2060_CR39","doi-asserted-by":"crossref","first-page":"S829","DOI":"10.1093\/infdis\/jix397","volume":"216","author":"M Noguera-Julian","year":"2017","unstructured":"Noguera-Julian, M. et al. Next-generation human immunodeficiency virus sequencing for patient management and drug resistance surveillance. J. Infect. Dis. 216, S829\u2013S833 (2017).","journal-title":"J. Infect. Dis."},{"key":"2060_CR40","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"2060_CR41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"2060_CR42","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"2060_CR43","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/molbev\/mst010","volume":"30","author":"K Katoh","year":"2013","unstructured":"Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772\u2013780 (2013).","journal-title":"Mol. Biol. Evol."},{"key":"2060_CR44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.meegid.2013.04.032","volume":"19","author":"AC Pineda-Pe\u00f1a","year":"2013","unstructured":"Pineda-Pe\u00f1a, A. C. et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect. Genet. Evol. 19, 337\u2013348 (2013).","journal-title":"Infect. Genet. Evol."},{"key":"2060_CR45","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/bioinformatics\/btq706","volume":"27","author":"KP Schliep","year":"2011","unstructured":"Schliep, K. P. phangorn: phylogenetic analysis in R. Bioinformatics 27, 592\u2013593 (2011).","journal-title":"Bioinformatics"},{"key":"2060_CR46","doi-asserted-by":"crossref","first-page":"e87334","DOI":"10.1371\/journal.pone.0087334","volume":"9","author":"A Kawana-Tachikawa","year":"2014","unstructured":"Kawana-Tachikawa, A. et al. Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. PLoS ONE 9, e87334 (2014).","journal-title":"PLoS ONE"},{"key":"2060_CR47","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/infdis\/jis379","volume":"206","author":"H Yang","year":"2012","unstructured":"Yang, H. et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J. Infect. Dis 206, 552\u2013561 (2012).","journal-title":"J. Infect. Dis"},{"key":"2060_CR48","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fimmu.2020.00418","volume":"11","author":"M Ross-Umbert","year":"2020","unstructured":"Ross-Umbert, M. In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 Kick&Kill Clinical Trial. Front. Immunol 11, 418 (2020).","journal-title":"Front. Immunol"},{"key":"2060_CR49","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","volume":"566","author":"KM Bruner","year":"2019","unstructured":"Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120\u2013125 (2019).","journal-title":"Nature"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02060-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02060-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02060-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:40:30Z","timestamp":1733960430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02060-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2060"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-02060-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"3 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.B., B.M. and A.L.L. are co-inventors of the HTI immunogen (patent application PCT\/EP2013\/051596). C.B., B.M. and I.M. are co-inventors of US patent application no. 62\/935,519 and US patent application no. 62\/851,546, which have relevance to the vaccine regimen used in this study. B.M. reports consultancy personal fees from AELIX Therapeutics SL, as well as speakers\u2019 fees from Gilead, Janssen and ViiV Healthcare, outside the submitted work. C.B. is co-founder, CSO and shareholder of AELIX Therapeutics SL and serves as an advisor for Tendel Therapies and OmniScope, outside the submitted work. M.N.-J. is co-founder and shareholder of Nano1Health SL, outside the scope of the submitted work. I.M. is a shareholder of, and acts as a consultant to, AELIX Therapeutics SL. He is also the CMO of Orion Biotechnology, outside the scope of the submitted work. J.M. has received research funding, consultancy fees and lecture sponsorships from, and has served on advisory boards for, various laboratories (MSD, Abbvie, Boehringer Ingelheim, Gilead Sciences, Viiv Healthcare, Janssen-Cilag and Bristol-Myers-Squibb). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}